JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Machine learning-based integration develops a multiple programmed cell death signature for predicting the clinical outcome and drug sensitivity in colorectal cancer

  • 0Central Laboratory, The Second Affiliated Hospital of Guilin Medical University.
Anti-Cancer Drugs +

|

August 12, 2024

|

August 12, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study introduces a novel Multiple Programmed Cell Death Index (MPCDI) to predict colorectal cancer (CRC) patient survival and guide treatment. The MPCDI effectively stratifies risk, analyzes immune infiltration, and predicts response to therapies, aiding personalized medicine for CRC.

Area Of Science

  • Oncology
  • Computational Biology
  • Immunology

Background

  • Programmed cell death (PCD) patterns are linked to tumorigenesis and cancer treatment.
  • The combined role of multiple PCD patterns in colorectal cancer (CRC) is not well understood.

Purpose Of The Study

  • To develop a Multiple Programmed Cell Death Index (MPCDI) for risk stratification and prognostic prediction in colorectal cancer (CRC).
  • To analyze immune cell infiltration and predict chemotherapeutic drug sensitivity in CRC patients based on the MPCDI.

Main Methods

  • Utilized two machine learning algorithms to create an MPCDI based on 19 PCD patterns.
  • Validated the MPCDI in TCGA-COAD, GSE17536, and GSE29621 cohorts.
  • Assessed immune infiltration, TIDE scores, immunophenoscores, and drug sensitivity.

Main Results

  • The MPCDI effectively distinguished survival outcomes and served as an independent prognostic factor for CRC patients.
  • Higher MPCDI scores correlated with increased overall immune infiltration but suggested reduced efficacy of immune checkpoint inhibition therapies.
  • MPCDI predicted differential sensitivity to various chemotherapeutic agents, offering guidance for drug selection.

Conclusions

  • The MPCDI is a novel clinical classifier for accurately distinguishing CRC patients who may benefit from immunotherapy.
  • MPCDI facilitates the development of personalized treatment strategies for colorectal cancer.
  • MPCDI aids in predicting patient response to specific chemotherapies and immunotherapies.